A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 21 Nov 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2018.
- 21 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 1 Jan 2018.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.